Managers / Q1 2025 · view latest →
TYBOURNE CAPITAL MANAGEMENT (HK) LTD
CIK 0001553936 · SUITES 818-822, 8/F, BANK OF AMERICA, TOWER, 12 HARCOURT ROAD,, HONG KONG, K3, XXXXX · 852-3983-6800
Summary
Tybourne Capital Management (Hk) Ltd reported $24M in U.S.-listed holdings across 5 positions for Q1 2025.
The portfolio is heavily concentrated: Acelyrin Inc Slrn US alone accounts for 30.5% of reported value.
Compared with Q4 2024, the fund opened 0 new positions and exited 28.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 48.7% · $11M
- Other · 30.5% · $7M
- ADR · 20.8% · $5M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CPCANADIAN PACIFIC KANSAS CITY (CP US) | SOLD OUT | −625.9K | 0 | −$45M | $0 |
| IQVIQVIA HOLDINGS INC (IQV US) | SOLD OUT | −199.3K | 0 | −$39M | $0 |
| ADSKAUTODESK INC (ADSK US) | SOLD OUT | −129.8K | 0 | −$38M | $0 |
| EPAMEPAM SYSTEMS INC (EPAM US) | SOLD OUT | −135.5K | 0 | −$32M | $0 |
| LPLALPL FINANCIAL HOLDINGS INC (LPLA US) | SOLD OUT | −77.3K | 0 | −$25M | $0 |
| DASHDOORDASH INC - A (DASH US) | SOLD OUT | −148.9K | 0 | −$25M | $0 |
| LSCCLATTICE SEMICONDUCTOR CORP (LSCC US) | SOLD OUT | −384.7K | 0 | −$22M | $0 |
| TXNTEXAS INSTRUMENTS INC (TXN US) | SOLD OUT | −112.5K | 0 | −$21M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ACELYRIN INC (SLRN US) | COM | 30.48% | $7M | 2.91M |
| 2 | TSHATAYSHA GENE THERAPIES INC (TSHA US)history → | COM SHS | 21.83% | $5M | 3.70M |
| 3 | BCYCBICYCLE THERAPEUTICS LTD-ADR (BCYC US)history → | SPONSORED ADS | 20.77% | $5M | 576.3K |
| 4 | FBRXFORTE BIOSCIENCES INC (FBRX US)history → | COM NEW | 20.42% | $5M | 620.0K |
| 5 | ZNTLZENTALIS PHARMACEUTICALS INC (ZNTL US)history → | COM | 6.49% | $2M | 961.5K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $31M | 4 | Nov 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $35M | 6 | Aug 1, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $24M | 5 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $398M | 37 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $357M | 34 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $492M | 40 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $585M | 41 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $671M | 39 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $716M | 41 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $925M | 49 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $993M | 49 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $1.0B | 27 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $1.0B | 26 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $1.4B | 27 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $1.7B | 30 | May 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $3.4B | 26 | Feb 25, 2022 | RESTATEMENT | changes · EDGAR ↗ |
| Q3 2021 | $4.0B | 24 | Oct 27, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $4.7B | 29 | Jul 22, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $4.6B | 32 | Apr 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $4.8B | 31 | Feb 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $4.1B | 29 | Nov 9, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $3.3B | 21 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $2.7B | 21 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $2.6B | 13 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $2.3B | 12 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $2.8B | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $2.6B | 11 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $2.2B | 9 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.